MedTrace Logo

A Treatment Legacy Effect of Metformin in Obese Women With PCOS

NCT04566718 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2020-11-05

No results posted yet for this study

Summary

Metformin has multiple health promoting effects and it may serve as a preventive measure for individuals who are at high risk for metabolic complications.

According to the latest international guidelines it should be considered as an adjunct therapy to lifestyle intervention in all overweight/obese women with PCOS, independently of their glucose homeostasis and menstrual regularity. However, there is no clear answer for how long metformin should be prescribed in this subset of women with PCOS and for how long the beneficial impact would sustain after treatment cessation.

The investigators compared the consequences of metformin withdrawal after long-term therapy as opposed to the consequences of metformin suspension after short term therapy in overweight/obese women with PCOS that had previously responded to metformin by means of moderate weight loss, improved menstrual frequency and sustained normal glucose homeostasis.

Conditions

  • PCOS

Interventions

DRUG

Metformin

metformin cessation

Sponsors & Collaborators

  • University Medical Centre Ljubljana

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-25
Primary Completion
2019-12-04
Completion
2020-02-01

Countries

  • Slovenia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04566718 on ClinicalTrials.gov